Epizyme’s Blood Cancer Drug Studies Will Continue; Shares Fall

Shares of Epizyme Inc. fell Monday after investors were disappointed that preliminary data from the company’s mid-stage study of its blood cancer drug didn’t live up to the high expectations set by an earlier trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.